Evaluation of Cell Death Caused by Triterpene Glycosides and Phenolic Substances from Cimicifuga racemosa Extract in Human MCF-7 Breast Cancer Cells(Pharmacognosy)
スポンサーリンク
概要
- 論文の詳細を見る
We previously reported that the antiproliferative effect of an isopropanolic-aqueous extract of black cohosh (iCR) on MCF-7 estrogen-responsive breast cancer cell line was due to the induction of apoptosis. Here we address the question to what extent apoptosis induction can be ascribed to one of the two major fractions of iCR, the triterpene glycosides (TTG) or the cinnamic acid esters (CAE). Furthermore, as black cohosh is routinely administered orally, we studied whether its pharmacological effects would withstand simulated liver metabolism. The antiproliferative activity of TTG and CAE as well as of rat liver microsomal S9 fraction-pretreated iCR on MCF-7 cells were investigated by WST-1 assay. The features of cell death induced were tested for apoptosis by flow cytometry (light scatter characteristics, Annexin V binding). Irrespective of S9-pretreatment, 72 h iCR treatment induced a dose-dependent down regulation of cell proliferation with the same IC_<50> of 55.3 μg/ml dry residue which corresponds to 19.3 μg/ml TTG and 2.7 μg/ml CAE. The degree of apoptotic MCF-7 cells was also comparable. Both, isolated TTG and CAE fractions inhibited cell growth, the IC_<50> being 59.3 μg/ml and 26.1 μg/ml, respectively. Interestingly, whereas IC_<50> and apoptosis induction correspond well for the whole extract, TTG and CAE fractions induced apoptosis at concentrations (25 and 5 μg/ml) well below those required for significant growth inhibition. Observation of this study firstly showed that the cell death induced by iCR withstood a metabolic activation system. In addition, TTG and CAE compounds significantly contributed to its apoptotic effect, CAE being the more potent inhibitor of proliferation and apoptosis inducer.
- 公益社団法人日本薬学会の論文
- 2004-12-01
著者
-
Reichling Juergen
Institute Of Pharmacy And Molecular Biotechnology University Of Heidelberg
-
Reichling Juergen
スイス
-
HOSTANSKA Katarina
Department of Internal Medicine F GEL 102, University Hospital Zurich
-
NISSLEIN Thomas
Research and Development Department, Schaper & Brummer GmbH & Co., KG
-
FREUDENSTEIN Johannes
Research and Development Department, Schaper & Brummer GmbH & Co., KG
-
SALLER Reinhard
Department of Internal Medicine F GEL 102, University Hospital Zurich
-
Hostanska Katarina
Department Of Internal Medicine F Gel 102 University Hospital Zurich
-
Freudenstein Johannes
Research And Development Department Schaper & Brummer Gmbh & Co. Kg
-
Nisslein Thomas
Research And Development Department Schaper & Brummer Gmbh & Co. Kg
-
Saller Reinhard
Department Of Internal Medicine F Gel 102 University Hospital Zurich